Randall Michael Giuffre - 01 Jun 2023 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Director
Signature
/s/ Amy E. Culbert, attorney-in-fact
Issuer symbol
DMAC
Transactions as of
01 Jun 2023
Net transactions value
$0
Form type
4
Filing time
02 Jun 2023, 16:02:20 UTC
Previous filing
03 Jan 2023
Next filing
26 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 295,355 01 Jun 2023 Direct F1
holding DMAC Voting Common Shares, no par value per share 25,573 01 Jun 2023 See footnote F2
holding DMAC Voting Common Shares, no par value per share 21,070 01 Jun 2023 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Award $0 +16,968 $0.000000 16,968 01 Jun 2023 Common Shares 16,968 $2.73 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 64,959 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.
F2 These voting common shares are held by 424822 Albert Ltd, of which Michael Giuffre has sole voting and dispositive power.
F3 Vests in four nearly equal quarterly installments over one year.